Eli Lilly and Resilience Boost Manufacturing for Diabetes and Weight-Loss Drugs 

Eli Lilly is putting $750 million toward expanding its manufacturing network for drug delivery devices. As part of the move, contract manufacturer Resilience will ramp up production of injectable pens, specifically the KwikPen system, which is used for Lilly’s popular metabolic, diabetes, and obesity medications. The goal is simple: meet massive long-term demand for these treatments.

Resilience is currently tuning up its expanded facility to get it fully operational. The site focuses on specialized devices for injectable drugs, including a newly FDA-approved multidose format. This single pen holds four full medication doses, making it much easier for patients to manage their treatments.

This expansion is a big boost for Resilience’s workforce. The company expects the added capacity to create hundreds of new jobs, eventually bringing its total headcount to around 1,400 people. This site is just one piece of Resilience’s broader manufacturing network across the country.

Since launching a few years ago, Resilience has grown remarkably fast. Backed by over $800 million in initial venture capital, the company went on to raise nearly $2.5 billion through additional funding rounds and a U.S. Department of Defense loan. Along the way, it has locked in major manufacturing deals with several top global drugmakers and recently consolidated its corporate leadership into a single headquarters.

This isn’t a new relationship. The two companies kicked off a 10-year partnership a few years back, and Resilience has already produced more than 150 million doses for Lilly. This latest investment builds right on top of that foundation.